6.
Prem K, Cook A, Jit M
. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017; 13(9):e1005697.
PMC: 5609774.
DOI: 10.1371/journal.pcbi.1005697.
View
7.
Adil Mahmoud Yousif N, Tsoungui Obama H, Ngucho Mbeutchou Y, Kwamou Ngaha S, Kayanula L, Kamanga G
. The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement. PLoS One. 2021; 16(4):e0245417.
PMC: 8061987.
DOI: 10.1371/journal.pone.0245417.
View
8.
Moore S, Hill E, Tildesley M, Dyson L, Keeling M
. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. Lancet Infect Dis. 2021; 21(6):793-802.
PMC: 7972312.
DOI: 10.1016/S1473-3099(21)00143-2.
View
9.
Amaku M, Covas D, Coutinho F, Azevedo R, Massad E
. Modelling the impact of delaying vaccination against SARS-CoV-2 assuming unlimited vaccine supply. Theor Biol Med Model. 2021; 18(1):14.
PMC: 8319712.
DOI: 10.1186/s12976-021-00143-0.
View
10.
Borges M, Ferreira L, Poloni S, Maria Bagattini A, Franco C, Quarti Machado da Rosa M
. Modelling the impact of school reopening and contact tracing strategies on Covid-19 dynamics in different epidemiologic settings in Brazil. Glob Epidemiol. 2022; 4:100094.
PMC: 9652103.
DOI: 10.1016/j.gloepi.2022.100094.
View
11.
Johnson D, Lulla V
. Predicting COVID-19 community infection relative risk with a Dynamic Bayesian Network. Front Public Health. 2022; 10:876691.
PMC: 9650227.
DOI: 10.3389/fpubh.2022.876691.
View
12.
Di Fusco M, Marczell K, Deger K, Moran M, Wiemken T, Cane A
. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022; 25(1):605-617.
DOI: 10.1080/13696998.2022.2071427.
View
13.
Pal D, Ghosh D, Santra P, Mahapatra G
. Mathematical Analysis of a COVID-19 Epidemic Model by Using Data Driven Epidemiological Parameters of Diseases Spread in India. Biophysics (Oxf). 2022; 67(2):231-244.
PMC: 9244063.
DOI: 10.1134/S0006350922020154.
View
14.
Badfar E, Jalaeian Zaferani E, Nikoofard A
. Design a robust sliding mode controller based on the state and parameter estimation for the nonlinear epidemiological model of Covid-19. Nonlinear Dyn. 2021; 109(1):5-18.
PMC: 8572654.
DOI: 10.1007/s11071-021-07036-4.
View
15.
Li K, Zhao Z, Wei H, Rui J, Huang J, Guo X
. Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants - China, 2021. China CDC Wkly. 2021; 3(50):1071-1074.
PMC: 8671839.
DOI: 10.46234/ccdcw2021.259.
View
16.
Mayfield H, Lau C, Sinclair J, Brown S, Baird A, Litt J
. Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine. Vaccine. 2022; 40(22):3072-3084.
PMC: 8989774.
DOI: 10.1016/j.vaccine.2022.04.004.
View
17.
Marin-Hernandez D, Nixon D, Hupert N
. Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany. Hum Vaccin Immunother. 2021; 17(8):2451-2453.
PMC: 8475553.
DOI: 10.1080/21645515.2021.1872344.
View
18.
Nino-Torres D, Rios-Gutierrez A, Arunachalam V, Ohajunwa C, Seshaiyer P
. Stochastic modeling, analysis, and simulation of the COVID-19 pandemic with explicit behavioral changes in Bogotá: A case study. Infect Dis Model. 2022; 7(1):199-211.
PMC: 8718868.
DOI: 10.1016/j.idm.2021.12.008.
View
19.
Worobey M
. Dissecting the early COVID-19 cases in Wuhan. Science. 2021; 374(6572):1202-1204.
DOI: 10.1126/science.abm4454.
View
20.
Szanyi J, Wilson T, Howe S, Zeng J, Andrabi H, Rossiter S
. Epidemiologic and economic modelling of optimal COVID-19 policy: public health and social measures, masks and vaccines in Victoria, Australia. Lancet Reg Health West Pac. 2023; 32:100675.
PMC: 9851841.
DOI: 10.1016/j.lanwpc.2022.100675.
View